(Q24241945)

4

0 references

author name string

Yan Gong

1

0 references

Zhi Bi Huang

2

0 references

Erik Christensen

Cochrane Database of Systematic Reviews

3

0 references

publication date

16 July 2008

0 references

published in

0 references

cites work

Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Characterisation of patients with a complete biochemical response to ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Ursodeoxycholic acid (UDCA) in the treatment of chronic cholestatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Ursodeoxycholic acid therapy for primary biliary cirrhosis. A 10-year British single-centre population-based audit of efficacy and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Ursodeoxycholic acid in primary biliary cirrhosis: no evidence for toxicity in the stages I to III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Effect of ursodeoxycholic acid in chronic hepatitis and primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Serial quantitative liver function tests in patients with primary biliary cirrhosis: a prospective long-term study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Subgroup analysis and other (mis)uses of baseline data in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

A perfect correlate does not a surrogate make

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Uncertainty method improved on best-worst case analysis in a binary meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Ursodeoxycholic acid for primary biliary cirrhosis: lesson for the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Hepatology may have problems with putative surrogate outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Epidemiology and natural history of primary biliary cirrhosis in a US community

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Agreement between reported use of interventions for liver diseases and research evidence in Cochrane systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Patients and patience: the pitfalls of primary biliary cirrhosis trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

A consumer's guide to subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Survival algorithms and outcome analysis in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past--issues for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

The epidemiology of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Analysing the relationship between treatment effect and underlying risk in meta-analysis: comparison and development of approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

How should meta-regression analyses be undertaken and interpreted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Ursodeoxycholic acid for primary biliary cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Ursodeoxycholic acid treatment lowers the serum level of antibodies against pyruvate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Effect of different doses of ursodeoxycholic acid in chronic liver disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Expression and therapeutic response related to apolipoprotein E polymorphism in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Biochemical and histological changes after more than four years of treatment of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Combination therapy with ursodeoxycholic acid and colchicine for primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Autoimmune conditions associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Fatigue in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021

Xanthomatous biliary cirrhosis; a clinical syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000551.PUB2

7 January 2021